Raymond James reinstates Outperform on Omega Healthcare Invts

0 min read     Updated on 17 Jun 2026, 08:13 PM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

Raymond James analyst David Rodgers reinstated an Outperform rating on Omega Healthcare Invts and set a price target of $50.

powered bylight_fuzz_icon
43253024

*this image is generated using AI for illustrative purposes only.

Raymond James analyst David Rodgers has reinstated an Outperform rating on Omega Healthcare Invts, announcing a price target of $50. The rating update highlights the firm's positive stance on the company's stock performance potential.

Rating and Price Target

The reinstatement of the Outperform rating accompanies a specific price objective set by the analyst. The following table summarizes the key details of the rating action:

Metric Value
Rating Outperform
Price Target $50

Analyst Coverage

David Rodgers, the analyst at Raymond James, provided the assessment on Omega Healthcare Invts. The stock is listed on the NYSE under the ticker symbol OHI.

What specific factors could drive Omega Healthcare's stock to reach the $50 price target?

How might recent changes in the healthcare real estate sector impact Omega's growth prospects?

What are the potential risks that could hinder the company from achieving the Outperform rating?

like15
dislike

Truist lowers Omega Healthcare price target to $46

0 min read     Updated on 09 Jun 2026, 09:18 PM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

Truist Securities analyst Michael Lewis maintains a Hold rating on Omega Healthcare Investors, lowering the price target to $46 from $48. The adjustment reflects a revised valuation outlook.

powered bylight_fuzz_icon
42565699

*this image is generated using AI for illustrative purposes only.

Truist Securities analyst Michael Lewis has maintained a Hold rating on Omega Healthcare Investors while reducing the price target to $46 from $48. The revised target indicates a recalibrated valuation following a review of the company's current market position.

Rating and Price Target Adjustment

The decision to lower the price target comes as the firm assesses the stock's potential upside against prevailing market conditions. Despite the reduction, the Hold rating suggests that the stock is expected to perform in line with the broader market.

Metric Previous Revised
Rating Hold Hold
Price Target $48 $46

Omega Healthcare Investors continues to operate under the ticker OHI on the NYSE. The latest guidance from Truist Securities provides investors with an updated benchmark for the stock's performance expectations.

What specific market conditions prompted Truist to recalibrate Omega Healthcare Investors' valuation?

How might this price target adjustment influence investor sentiment toward the healthcare REIT sector?

What upcoming earnings or operational milestones could shift the stock's performance relative to the broader market?

like19
dislike
Must Read Next

Earnings

Corporate Actions

Stocks